technology

Sleepio becomes first digital therapeutic to receive NICE guidance

Date: May 21, 2022 Omkar Patwardhan Omkar Patwardhan
Sleepio becomes first digital therapeutic to receive NICE guidance 
Big Health has reportedly become the first digital therapeutics company for mental health issues to receive guidance from the NICE (National Institute for Health and Care Excellence). This non-departmental public body has recommended Sleepio as one of the cost-saving treatment options for insomnia.



According to the NICE guidance, Sleepio, a digital therapeutic for insomnia, is an effective and safe treatment for patients who would otherwise have access to only the current standard of care, including mediation and sleep hygiene advice.



Moreover, NICE has confirmed Sleepio as a cost-saving treatment for the NHS (National Health Service), with evidence showing its reduction in prescribing costs and GP appointments through instant access to CBT-I (cognitive behavioral therapy for insomnia), where face-to-face CBT-I therapy is unavailable.



Studies revealed that around one-third of UK adults experience insomnia symptoms each week.



The NICE MTAC (Medical Technologies Advisory Committee) has evaluated the industry-leading evidence base of over 28 clinical studies of Sleepio, including 12 randomized controlled trials on thousands of patients. The therapeutic can help 76% of insomnia patients achieve clinical improvement, as per peer-reviewed clinical trials.



According to Dr. Nick Broughton, Oxford Health NHS Foundation Trust’s CEO and Oxford AHSN (Academic Health and Science Network)’s Board Member, both the associations are thrilled to have played a crucial role in the flagship implementation of Sleepio in the Thames Valley. They are also anticipating an extensive availability of this therapeutic across the country.



As per the statement made by Big Health’s Chief Scientist Professor and Co-founder, Colin Espie, the company has shown excitement about Sleepio becoming the first-ever digital therapeutic to gain NICE guidance following rigorous evaluation.



Positive outcomes via NICE guidance are an important step towards developing solutions powered by scalable and clinically proven digital tech. This can consequently help reduce the NHS care backlog and offer safe, accessible, and evidence-based support for everyone in need.



Source credit:



https://www.businesswire.com/news/home/20220519005804/en/Sleepio-Is-the-First-Ever-Digital-Therapeutic-to-Receive-NICE-Guidance-Confirming-Clinical-and-Cost-Effectiveness

About the author

View All Posts

Omkar Patwardhan

Omkar Patwardhan started his professional career in the hospitality industry. Having nurtured a deep-sated passion for words however, he found his way into content writing and now pens down articles for numerous websites, including News Origins, spanning the sectors of business, finance, and technology.